Citation from the publications of

Najjar, Souhel; Pearlman, Daniel; Miller, Douglas C; Devinsky, Orrin
"Refractory epilepsy associated with microglial activation"
Neurologist 2011 Sep; 17(5):249-254
BACKGROUND: : Experimental and clinical studies support a pathogenic role of microglial activation and proliferation (MAP) in epileptogenesis. METHODS: : From a consecutive series of 319 surgically treated epilepsy cases, we retrospectively reviewed the histopathological sections of 92 cases to define the prevalence and severity of MAP after excluding the other 227 because of coexisting disorders that might contribute to MAP. Severity of MAP was compared with underlying abnormalities. We assessed the response to intravenous immunoglobulin and plasmapheresis in one patient with severe MAP who had failed multiple antiepileptic drugs and epilepsy surgery. RESULTS: : MAP was detected with routine (hematoxylin and eosin) stain in 46 of 92 cases (50%). MAP was mild in 32 cases (69.6%), moderate in 12 (26.1%), and severe in 2 (4.3%). The prevalence and severity of MAP were independent of underlying abnormalities. Immunomodulatory therapy was followed by a greater than 90% reduction in seizure activity in the treated patient. CONCLUSION: : MAP is prevalent in resected human epilepsy tissue. Failure to down-regulate MAP contributes to chronic neuronal hyperexcitability. We hypothesize that MAP initiates a cycle of inflammation-induced seizures and seizure-induced inflammation. Microglia-driven epilepsy may be a primary pathogenic process in a small number of cases, as suggested by the pathology and therapeutic response in our patient, but may contribute to epileptogenesis in many more

Check for full text:  

# 137008 (MEDL:21881466)


This publication list a product of the NYU Faculty Bibliography.